Evidence map›Paper›PMID 40853486›Full record

ArticleCancer immunology, immunotherapy : CII2025

Spautin-1 inhibits the growth of diffuse large B-cell lymphoma by inducing mitochondrial damage-mediated PANoptosis and anti-tumor immunity.

Jingjing Wu, Yuan Deng, Yong Gao, Bin Wei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. PANoptosis and Immune Remodeling in the Tumor Microenvironment.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jingjing Wu *Department of Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Yuan Deng *Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Yong GaoDepartment of Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China. hayygaoy@njmu.edu.cn.
Bin WeiDepartment of Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China. weibin@njmu.edu.cn.

Funding

Huai'an Natural Science Research Program HAB202205Innovation key Talent Program of Huai'an First People's Hospital ZC202201National Natural Science Foundation of China 82103318Young Innovative Talent Program of Huai'an First People's Hospital QC202213
6 · The paper itself

Abstract

The prognosis of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Therefore, searching for new therapeutic agents is particularly important to improve therapeutic efficacy. Targeting the ubiquitin-proteasome system is a potential therapeutic strategy for treating DLBCL. In this study, we investigated the role of the deubiquitase inhibitor Spautin-1 in the treatment of DLBCL. Spautin-1 significantly inhibited the growth of DLBCL, including the growth of cells and transplanted tumors in mice. Notably, Spautin-1 showed enhanced tumor suppression in immune-competent versus immunodeficient mice models, mediated by CD8

Indexed as

Lymphoma, Large B-Cell, DiffuseMitochondriaAnimalsCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationFemaleHumansMicePrognosisXenograft Model Antitumor AssaysAnti-tumor immunityCell growthDiffuse large B-cell lymphomaMitochondrial damagePANoptosisSpautin-1

Identifiers

PMID40853486
PMCPMC12378856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.